Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$127,477 | -$60,366 | -$28,893 | -$26,350 |
| Dep. & Amort. | $2,133 | $1,707 | $1,051 | $586 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $8,357 | $2,220 | $929 | $7,250 |
| Change in WC | $7,857 | $3,424 | -$10,327 | -$4,491 |
| Other Non-Cash | -$5,120 | $605 | $1,127 | $850 |
| Operating Cash Flow | -$114,250 | -$52,410 | -$36,113 | -$22,155 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,205 | -$621 | -$768 | -$1,289 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$489,997 | -$54,847 | -$56,495 | $0 |
| Inv. Sales/Matur. | $323,636 | $46,683 | $43,166 | $0 |
| Other Inv. Act. | $7,664 | $0 | $0 | $0 |
| Investing Cash Flow | -$160,902 | -$8,785 | -$14,097 | -$1,289 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$956 | -$781 | -$249 | -$41 |
| Stock Issued | $341,171 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$3,102 | $58,899 | $12,129 | $72,564 |
| Financing Cash Flow | $337,113 | $58,118 | $11,880 | $72,523 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $61,961 | -$3,077 | -$38,330 | $49,079 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $35,212 | $38,289 | $76,619 | $27,540 |
| End Cash | $97,173 | $35,212 | $38,289 | $76,619 |
| Free Cash Flow | -$116,455 | -$53,031 | -$36,881 | -$23,444 |